Effect of Atorvastatin and Clopidogrel Co-Administration After Coronary Stenting in Korean Patients With Stable Angina |
Kim, Goeng-Bae
(Cardiovascular Center, Sun General Hospital)
Kim, Jeong-Kyung (Cardiovascular Center, Sun General Hospital) Park, Sul (Cardiovascular Center, Sun General Hospital) Jeong, Jae-Jin (Cardiovascular Center, Sun General Hospital) Yoon, Hyung-Sik (Cardiovascular Center, Sun General Hospital) Ko, Sang-Hun (Cardiovascular Center, Sun General Hospital) Ko, Jae-Ee (Cardiovascular Center, Sun General Hospital) Park, Soo-Jin (Cardiovascular Center, Sun General Hospital) Nam, Seon-Woo (Department of Neurology, Sun General Hospital) Lee, Jae-Hwan (Cardiovascular Center, Chungnam National University Hospital) Hyon, Min-Soo (Department of Cardiology, Soonchunhyang University of College of Medicine) |
1 | CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39. DOI ScienceOn |
2 | Chae SC. Antiplatelet agents in high-risk patients with coronary artery disease. Korean Circ J 2004;34:23-7. |
3 | Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared ticlopidine in combination with as-pirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000;102:624-9. DOI ScienceOn |
4 | Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. DOI ScienceOn |
5 | Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomiz-ed and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14. |
6 | Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9. DOI ScienceOn |
7 | Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-71. DOI ScienceOn |
8 | Schomig A, Mehilli J, Holle H, et al. Statin treatment following coronary stenting and one-year survival. J Am Coll Cardiol 2002;40:854-61. DOI ScienceOn |
9 | Baek JH, Choe KH, Jun JE, et al. Multicenter clinical trial of atorvastatin in patients with hypercholesterolemia. Korean Circ J 2001;31:434-41. |
10 | Yun KH, Park HY, Choi JH, et al. Comparison of efficacy and safety after administering high potency statin to high risk patients: rosuvastatin 10 mg versus Atorvastatin 20 mg. Korean Circ J 2007;37:154-60. DOI ScienceOn |
11 | Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992;44:527-32. DOI ScienceOn |
12 | Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72:313-7. |
13 | Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological ac-tivity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891-6. |
14 | Clarke TA, Wakell LA. The metabolism of clopidogrel is catalyzed by human cytochrome p450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9. DOI ScienceOn |
15 | Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the abi-lity of clopidogrel to inhibit platelet aggregation: a new drug-drug in-teraction. Circulation 2003;107:32-7. DOI ScienceOn |
16 | Neubauer H, Günesdogan B, Hanefeld C, Spiecker M, Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study. Eur Heart J 2003;24:1744-9. DOI ScienceOn |
17 | Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomiz-ed, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4. DOI ScienceOn |
18 | Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92:285-8. DOI ScienceOn |
19 | Mitsios JV, Papathanasiou AI, Rodis FI, Elisaf M, Goudevenos JA, Tselepis AD. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004;109:1335-8. DOI ScienceOn |
20 | Serebruany VL, Midei MG, Malinin Al, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004;164:2051-7. DOI ScienceOn |
21 | Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA. Lack of clo-pidogrel-CYP3A4 statin interaction in patients with acute coronary syn-drome. Heart 2005;91:23-6. DOI ScienceOn |
22 | Geisler T, Zürn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008;29:1635-43. DOI ScienceOn |
23 | Hong SJ, Park JY, Kim KA, et al. Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome. Circ J 2009;73:1111-8. DOI ScienceOn |
24 | World Medical Association. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html (accessed 2 December 2008). |
25 | Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-13. DOI ScienceOn |
26 | Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-91. DOI ScienceOn |
27 | Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphism of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008;72:1165-9. DOI ScienceOn |
28 | Lee KH, Lee SW, Lee JW, et al. The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow P2Y21 assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation. Korean Circ J 2009; 39:512-8. DOI ScienceOn |
29 | Mach F, Senouf D, Fontana P, et al. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 2005;35:476-81. DOI ScienceOn |
30 | Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502. |
31 | Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequi-valence Studies. New York: Marcel Dekker;1999. |
32 | Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research. New York: Marcel Dekker;2003. |